MX2019012757A - Composicion farmaceutica para administracion oral que comprende enzalutamida. - Google Patents

Composicion farmaceutica para administracion oral que comprende enzalutamida.

Info

Publication number
MX2019012757A
MX2019012757A MX2019012757A MX2019012757A MX2019012757A MX 2019012757 A MX2019012757 A MX 2019012757A MX 2019012757 A MX2019012757 A MX 2019012757A MX 2019012757 A MX2019012757 A MX 2019012757A MX 2019012757 A MX2019012757 A MX 2019012757A
Authority
MX
Mexico
Prior art keywords
enzalutamide
pharmaceutical composition
orally administrable
containing pharmaceutical
administrable pharmaceutical
Prior art date
Application number
MX2019012757A
Other languages
English (en)
Inventor
Sakai Toshiro
Oba Shinsuke
Kojima Ryo
UMEMOTO Yoshiaki
Yoshida Takatsune
Namiki Sachie
Takagi Akira
Aoki Hajime
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2019012757A publication Critical patent/MX2019012757A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Se proporciona una composición farmacéutica para administración oral en donde se mejoran las propiedades de solubilidad y/o disolución de enzalutamida y se mantiene la sobresaturación. También se proporciona una composición farmacéutica para administración oral en donde se mejora la capacidad de absorción oral de enzalutamida. La composición farmacéutica para administración oral comprende enzalutamida y alcohol polivinílico.
MX2019012757A 2017-04-28 2018-04-27 Composicion farmaceutica para administracion oral que comprende enzalutamida. MX2019012757A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017090300 2017-04-28
PCT/JP2018/017159 WO2018199282A1 (ja) 2017-04-28 2018-04-27 エンザルタミドを含有する経口投与用医薬組成物

Publications (1)

Publication Number Publication Date
MX2019012757A true MX2019012757A (es) 2019-12-16

Family

ID=63920425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012757A MX2019012757A (es) 2017-04-28 2018-04-27 Composicion farmaceutica para administracion oral que comprende enzalutamida.

Country Status (10)

Country Link
US (1) US20200146977A1 (es)
EP (1) EP3616696A4 (es)
JP (1) JP7172997B2 (es)
KR (1) KR20190137920A (es)
CN (1) CN110573153B (es)
AU (1) AU2018256998B2 (es)
CA (1) CA3060366A1 (es)
MX (1) MX2019012757A (es)
RU (1) RU2019138248A (es)
WO (1) WO2018199282A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991484A1 (ru) 2012-09-11 2019-11-29 Лекарственные формы энзалутамида
JP7238509B2 (ja) * 2019-03-19 2023-03-14 三菱ケミカル株式会社 医薬錠剤
WO2021240206A1 (en) * 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
JP7414668B2 (ja) 2020-08-28 2024-01-16 信越化学工業株式会社 ポリビニルアルコール含有造粒物及び固形製剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
JPH10316576A (ja) * 1997-05-13 1998-12-02 Nissui Pharm Co Ltd キトサン含有錠剤
ME01992B (me) 2005-05-13 2012-10-30 Univ California Jedinjenje diarilhidantoina
WO2010029930A1 (ja) * 2008-09-12 2010-03-18 第一三共ヘルスケア株式会社 変色が抑制された安定な医薬製剤
MX2012009782A (es) 2010-02-24 2012-11-29 Medivation Prostate Therapeutics Inc Procesos para la sintesis de diariltiohidantoina y compuestos de diarilhidantoina.
MX357551B (es) * 2011-03-23 2018-07-13 Ironshore Pharmaceuticals & Dev Inc Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
EP2674149B1 (en) * 2012-06-15 2017-10-04 Shin-Etsu Chemical Co., Ltd. Method of preparing composite granule comprising low-substituted hydroxypropyl cellulose and rapid release preparation
JP2015534550A (ja) 2012-09-11 2015-12-03 ドクター レディズ ラボラトリーズ リミテッド エンザルタミドの多形形態およびその調製
EA201991484A1 (ru) * 2012-09-11 2019-11-29 Лекарственные формы энзалутамида
WO2014167428A2 (en) * 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
JP6133445B2 (ja) * 2014-01-30 2017-05-24 テイカ製薬株式会社 口腔内速崩壊性固形製剤用組成物
CN112402360A (zh) * 2014-02-05 2021-02-26 斯洛文尼亚莱柯制药股份有限公司 雄激素受体拮抗剂的固体药物组合物
WO2015120014A1 (en) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
SG11201607623XA (en) * 2014-04-25 2016-11-29 Chugai Pharmaceutical Co Ltd Preparation containing tetracyclic compound at high dose
US20180280302A1 (en) * 2015-01-20 2018-10-04 Merck Patent Gmbh Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer
JP6403615B2 (ja) * 2015-03-18 2018-10-10 日本酢ビ・ポバール株式会社 フィルムコーティング組成物並びに経口固形製剤及びその製造方法
JP2016056208A (ja) * 2016-01-15 2016-04-21 日本酢ビ・ポバール株式会社 フィルムコーティング組成物並びに経口固形製剤及びその製造方法

Also Published As

Publication number Publication date
JPWO2018199282A1 (ja) 2020-03-12
RU2019138248A3 (es) 2021-07-21
US20200146977A1 (en) 2020-05-14
CN110573153B (zh) 2023-04-04
JP7172997B2 (ja) 2022-11-16
EP3616696A4 (en) 2021-01-27
WO2018199282A1 (ja) 2018-11-01
KR20190137920A (ko) 2019-12-11
CN110573153A (zh) 2019-12-13
RU2019138248A (ru) 2021-05-28
CA3060366A1 (en) 2018-11-01
AU2018256998A1 (en) 2019-12-05
EP3616696A1 (en) 2020-03-04
AU2018256998B2 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
MX2019012757A (es) Composicion farmaceutica para administracion oral que comprende enzalutamida.
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
MX2015017964A (es) Inhibidores de bromodominio.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
EP3716767A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF RARE DISEASES
EP3706741A4 (en) PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
IN2013MU03583A (es)
EP3518918A4 (en) METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
EP3600259A4 (en) NEW PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBINE AND DERIVATIVES THEREOF AND METHODS FOR THE MANUFACTURE AND USE OF THEM
IL280083A (en) A pharmaceutical dosage form that can be administered orally and with a modified release
EP3697411A4 (en) NEW PHARMACEUTICAL COMPOSITION AND ITS USE
EP3849992A4 (en) Cd73 inhibitors and pharmaceutical uses thereof
EP3750537A4 (en) PHARMACEUTICAL COMPOSITION, EXCIPIENT FOR THE COMPOSITION AND USE OF THE COMPOSITION
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EP3533451A4 (en) APPLICATION OF PAEENIFLORIN-6'-O-BENZENE SULFONATE IN MEDICINE FOR THE TREATMENT OF SJÖGREN SYNDROME
EP3456711A4 (en) CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREFOR
EP3881843A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICAL COMPOSITION FOR IL-31 MEDIATED DISEASE
EP3817744A4 (en) IVOSIDENIB FORMS AND PHARMACEUTICAL COMPOSITIONS
EP3716975A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
EP3431107A4 (en) PARTICULARS OF A PHARMACEUTICAL COMPOSITION AND MOUTH-DISTURBING PREPARATION THEREOF
EP3674303A4 (en) NEW TRYPTOPHANE HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION WITH IT